RGS17: An emerging therapeutic target for lung and prostate cancers

Future Medicinal Chemistry

Volumn 5, Issue 9, 2013, Pages 995-1007

  Bodle, Christopher R ^a   MacKie, Duncan I ^a,b   Roman, David L ^a,b  

^a UNIVERSITY OF IOWA   (United States)

^b UNIVERSITY OF IOWA HOSPITALS AND CLINICS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DOPAMINE; G PROTEIN COUPLED RECEPTOR; GUANOSINE TRIPHOSPHATASE; PROTEIN INHIBITOR; RGS 17 PROTEIN; RGS PROTEIN; UNCLASSIFIED DRUG;

CANCER GROWTH; CANCER RESISTANCE; CHEMORESISTANCE; CHEMOTHERAPEUTIC RESISTANCE; DRUG SCREENING; ENZYME ACTIVITY; HIGH THROUGHPUT SCREENING; HUMAN; LUNG CANCER; MODULATION; NONHUMAN; ONCOLOGICAL PARAMETERS; OVARY CANCER; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVIEW; SIGNAL TRANSDUCTION; SUBSTANCE ABUSE; THERAPY RESISTANCE;

ANTINEOPLASTIC AGENTS; DOPAMINE; DRUG RESISTANCE, NEOPLASM; GTP-BINDING PROTEIN ALPHA SUBUNITS; HETEROTRIMERIC GTP-BINDING PROTEINS; HUMANS; LIGANDS; LUNG NEOPLASMS; MALE; PROSTATIC NEOPLASMS; RECEPTORS, OPIOID, MU; RGS PROTEINS; SIGNAL TRANSDUCTION;

EID: 84878714395     PISSN: 17568919     EISSN: 17568927     Source Type: Journal    
DOI: 10.4155/fmc.13.91     Document Type: Review

References (101)

1. Pierce KL, Premont RT, Lefkowitz RJ. Seven-transmembrane receptors. Nat. Rev. Mol. Cell Biol. 3(9), 639-650 (2002).
2. Dorsam RT, Gutkind JS. G-protein-coupled receptors and cancer. Nat. Rev. Cancer 7(2), 79-94 (2007).
3. Roman DL. Identification of ligands targeting RGS proteins high-throughput screening and therapeutic potential. Prog. Mol. Biol. Transl. Sci. 86, 335-356 (2009).
4. Sternweis PC, Robishaw JD. Isolation of two proteins with high affinity for guanine nucleotides from membranes of bovine brain. J. Biol. Chem. 259(22), 13806-13813 (1984).
5. Roman DL, Traynor Jr. Regulators of G protein signaling (RGS) proteins as drug targets: modulating g-protein-coupled receptor (GPCR) signal transduction. J. Med. Chem. 54(21), 7433-7440 (2011).
6. Zhong H, Neubig RR. Regulator of G protein signaling proteins: novel multifunctional drug targets. J. Pharmacol. Exp. Ther. 297(3), 837-845 (2001).
7. Dohlman HG, Thorner J. RGS proteins and signaling by heterotrimeric G proteins. J. Biol. Chem. 272(7), 3871-3874 (1997).
8. Druey KM, Blumer KJ, Kang VH, Kehrl JH. Inhibition of G-protein-mediated MAP kinase activation by a new mammalian gene family. Nature 379(6567), 742-746 (1996).
9. Koelle MR, Horvitz HR. EGL-10 regulates G protein signaling in the C. elegans nervous system and shares a conserved domain with many mammalian proteins. Cell 84(1), 11-11 (1996).
10. Siderovski DP, Hessel A, Chung S, Mak TW, Tyers M. A new family of regulators of G-protein-coupled receptors? Curr. Biol. 6(2), 211-212 (1996).
11. Cho H, Kehrl JH. Chapter 9 Regulation of immune function by G protein-coupled receptors, trimeric G Proteins, and RGS Proteins. In: Progress in Molecular Biology and Translational Science. Fisher RA (Ed.). Academic Press, MA, USA 249-298 (2009).
12. Grünebach F, Erndt S, Häntschel M, Heine A, Brossart P. Generation of antigen-specific CTL responses using RGS1 mRNA transfected dendritic cells. Cancer Immunol. Immunother. 57(10), 1483-1491 (2008).
13. Rangel J, Nosrati M, Leong SPL, et al. Novel role for RGS1 in melanoma progression. Am. J. Surg. Pathol. 32(8), 1207-1212 (2008).
14. Hurst JH, Mendpara N, Hooks SB. Regulator of G-protein signalling expression and function in ovarian cancer cell lines. Cell. Mol. Biol. Lett. 14(1), 153-174 (2009).
15. Wieland T, Lutz S, Chidiac P. Regulators of G protein signalling: a spotlight on emerging functions in the cardiovascular system. Curr. Opin. Pharmacol. 7(2), 201-207 (2007).
16. Terzi D, Stergiou E, King SL, Zachariou V. Regulators of G protein signaling in neuropsychiatric disorders. Prog. Mol. Biol. Transl Sci. 86, 299-333 (2009).
17. Traynor J. Regulator of G protein-signaling proteins and addictive drugs. Ann. NY Acad. Sci. 1187(1), 341-352 (2010).
18. Siderovski D, Harden T. The RGS protein superfamily. In: Handbook of Cell Signaling. Bradshaw RA, Dennis EA (Eds). Academic Press, MA, USA 631-638 (2003).
19. Snow BE, Krumins AM, Brothers GM, et al. A G protein gamma subunit-like domain shared between RGS11 and other RGS proteins specifies binding to Gbeta5 subunits. Proc. Natl Acad. Sci. USA 95(22), 13307-13312 (1998).
20. Ponting CP, Bork P. Pleckstrin's repeat performance: a novel domain in G-protein signaling? Trends Biochem. Sci. 21(7), 245-246 (1996).
21. Snow BE, Betts L, Mangion J, Sondek J, Siderovski DPD. Fidelity of G protein beta-subunit association by the G protein gamma-subunit-like domains of RGS6, RGS7, and RGS11. Proc. Natl Acad. Sci. USA 96(11), 6489-6494 (1999).
22. Makino ER, Handy JW, Li T, Arshavsky VY. The GTPase activating factor for transducin in rod photoreceptors is the complex between RGS9 and type 5 G protein beta subunit. Proc. Natl Acad. Sci. USA 96(5), 1947-1952 (1999).
23. Levay K, Cabrera JL, Satpaev DK, Slepak VZ. Gbeta5 prevents the RGS7-Galphao interaction through binding to a distinct Ggamma-like domain found in RGS7 and other RGS proteins. Proc. Natl Acad. Sci. USA 96(5), 2503-2507 (1999).
24. Hoffman GA, Garrison TR, Dohlman HG. Endoproteolytic processing of Sst2, a multidomain regulator of G protein signaling in yeast. J. Biol. Chem. 275(48), 37533-37541 (2000).
25. Snow BE, Hall RA, Krumins AM, et al. GTPase activating specificity of RGS12 and binding specificity of an alternatively spliced PDZ (PSD-95/Dlg/ZO-1) domain. J. Biol. Chem. 273(28), 17749-17755 (1998).
26. Schiff ML, Siderovski DP, Jordan JD, et al. Tyrosine-kinase-dependent recruitment of RGS12 to the N-type calcium channel. Nature 408(6813), 723-727 (2000).
27. Ponting CP. Raf-like Ras/Rap-binding domains in RGS12-and still-life-like signalling proteins. J. Mol. Med. (Berl.). 77(10), 695-698 (1999).
28. De Vries L, Elenko E, Hubler L, Jones TL, Farquhar MG. GAIP is membrane-anchored by palmitoylation and interacts with the activated (GTP-bound) form of G alpha i subunits. Proc. Natl Acad. Sci. USA 93(26), 15203-15208 (1996).
29. De Vries L, Mousli M, Wurmser A, Farquhar MG. GAIP, a protein that specifically interacts with the trimeric G protein G alpha i3, is a member of a protein family with a highly conserved core domain. Proc. Natl Acad. Sci. USA 92(25), 11916-11920 (1995).
30. Glick JL, Meigs TE, Miron A, Casey PJ. RGSZ1, a Gz-selective regulator of G protein signaling whose action is sensitive to the phosphorylation state of Gzalpha. J. Biol. Chem. 273(40), 26008-26013 (1998).
31. Jordan JD, Carey KD, Stork PJ, Iyengar R. Modulation of rap activity by direct interaction of Galpha(o) with Rap1 GTPase-activating protein. J. Biol. Chem. 274(31), 21507-21510 (1999).
32. Barker SA, Wang J, Sierra DA, Ross EM. RGSZ1 and Ret RGS: two of several splice variants from the gene RGS20. Genomics 78(3), 7-7 (2001).
33. Nunn C, Mao H, Chidiac P, Albert PR. RGS17/RGSZ2 and the RZ/A family of regulators of G-protein signaling. Semin. Cell Dev. Biol. 17(3), 390-399 (2006).
34. Mao H, Zhao Q, Daigle M, Ghahremani MH, Chidiac P, Albert PR. RGS17/RGSZ2, a novel regulator of Gi/o, Gz, and Gq signaling. J. Biol. Chem. 279(25), 26314-26322 (2004).
35. Doupnik CA, Xu T, Shinaman JM. Profile of RGS expression in single rat atrial myocytes. Acta Bioenerg. 1522(2), 97-107 (2001).
36. Larminie C, Murdock P, Walhin J-P, et al. Selective expression of regulators of G-protein signaling (RGS) in the human central nervous system. Brain Res. Mol. Brain Res. 122(1), 11-11 (2004).
37. Garzón J, Rodríguez-Muñoz M, López-Fando A, García-España A, Sánchez-Blázquez P. RGSZ1 and GAIP regulate mu-but not delta-opioid receptors in mouse CNS: role in tachyphylaxis and acute tolerance. Neuropsychopharmacology 29(6), 1091-1104 (2004).
38. Garzón J, Rodríguez-Muñoz M, López-Fando A, Sánchez-Blázquez P. The RGSZ2 protein exists in a complex with mu-opioid receptors and regulates the desensitizing capacity of Gz proteins. Neuropsychopharmacology 30(9), 1632-1648 (2005).
39. Rodríguez-Muñoz M, Bermúdez D, Sánchez- Blázquez P, Garzón J. Sumoylated RGS-Rz proteins act as scaffolds for Mu-opioid receptors and G-protein complexes in mouse brain. Neuropsychopharmacology 32(4), 842-850 (2007).
40. Garzón J, Rodríguez-Muñoz M, Vicente-Sánchez A, et al. SUMO-SIM interactions regulate the activity of RGSZ2 proteins. PLoS ONE 6(12), e28557-e28557 (2011).
41. Garzón J, Rodríguez-Muñoz M, Vicente-Sánchez A, Bailón C, Martínez-Murillo R, Sánchez-Blázquez P. RGSZ2 binds to the neural nitric oxide synthase PDZ domain to regulate mu-opioid receptor-mediated potentiation of the N-methyl-d-aspartate receptor-calmodulin-dependent protein kinase II pathway. Antioxid. Redox Signal. 15(4), 873-887 (2011).
42. Sánchez-Blázquez P, Rodríguez-Muñoz M, Bailón C, Garzón J. GPCRs promote the release of zinc ions mediated by nNOS/NO and the redox transducer RGSZ2 protein. Antioxid. Redox Signal. 17(9), 1163-1177 (2012).
43. Rose JJ, Taylor JB, Shi J, Cockett MI, Jones PG, Hepler Jr. RGS7 is palmitoylated and exists as biochemically distinct forms. J. Neurochem. 75(5), 2103-2112 (2000).
44. Witherow DS, Wang Q, Levay K, et al. Complexes of the G protein subunit gbeta 5 with the regulators of G protein signaling RGS7 and RGS9. Characterization in native tissues and in transfected cells. J. Biol. Chem. 275(32), 24872-24880 (2000).
45. Burchett SA. In through the out door: nuclear localization of the regulators of G protein signaling. J. Neurochem. 87(3), 551-559 (2003).
46. Zhang JH, Barr VA, Mo Y, Rojkova AM, Liu S, Simonds WF. Nuclear localization of G protein beta 5 and regulator of G protein signaling 7 in neurons and brain. J. Biol. Chem. 276(13), 10284-10289 (2001).
47. Chatterjee TK. Human RGS6 gene structure, complex alternative splicing, and role of N terminus and G protein -subunit-like (GGL) domain in subcellular localization of RGS6 splice variants. J. Biol. Chem. 278(32), 30261-30271 (2003).
48. Cho H, Kozasa T, Takekoshi K, De Gunzburg J, Kehrl JH. RGS14, a GTPase-Activating protein for Gia, attenuates Gia-and G13a-mediated signaling pathways. Mol. Pharmacol. 58, 569-576 (2000).
49. Chatterjee TK, Fisher RA. RGS12TS-S localizes at nuclear matrix-associated subnuclear structures and represses transcription: structural requirements for subnuclear targeting and transcriptional repression. Mol. Cell. Biol. 22(12), 4334-4345 (2002).
50. Meulmeester E, Melchior F. Cell biology: SUMO. Nature 452(7188), 709-711 (2008).
51. White FJ, Kalivas PW. Neuroadaptations involved in amphetamine and cocaine addiction. Drug Alcohol Depend. 51(1-2), 141-153 (1998).
52. Wang HY, Runyan S, Yadin E, Friedman E. Prenatal exposure to cocaine selectively reduces D1 dopamine receptor-mediated activation of striatal Gs proteins. J. Pharmacol. Exp. Ther. 273(1), 492-498 (1995).
53. Stanwood GD, Parlaman JP, Levitt P. Genetic or pharmacological inactivation of the dopamine D1receptor differentially alters the expression of regulator of G-protein signalling (Rgs) transcripts. Eur. J. Neurosci. 24(3), 806-818 (2006).
54. Maple AM, Perna MK, Parlaman JP, Stanwood GD, Brown RW. Ontogenetic quinpirole treatment produces long-lasting decreases in the expression of Rgs9, but increases Rgs17 in the striatum, nucleus accumbens and frontal cortex. Eur. J. Neurosci. 26(9), 2532-2538 (2007).
55. Brown RW, Perna MK, Schaefer TL, Williams MT. The effects of adulthood nicotine treatment on D2-mediated behavior and neurotrophins of rats neonatally treated with quinpirole. Synapse 59(5), 253-259 (2006).
56. Kostrzewa RM. Dopamine receptor supersensitivity. Neurosci. Biobehav. Rev. 19(1), 1-17 (1995).
57. Cook CD, Beardsley PM. Modulation of the discriminative stimulus effects of mu opioid agonists in rats: I. effects of dopamine D2/3 antagonists. Behav. Pharmacol. 15(1), 65-74 (2004).
58. Town T, Abdullah L, Crawford F, et al. Association of a functional mu-opioid receptor allele (+118A) with alcohol dependency. Am. J. Med. Genet. A. 88(5), 458-461 (1999).
59. Schinka JA, Town T, Abdullah L, et al. A functional polymorphism within the mu-opioid receptor gene and risk for abuse of alcohol and other substances. Mol. Psychiatry 7(2), 224-228 (2002).
60. Kim S-G, Kim C-M, Kang D-H, et al. Association of functional opioid receptor genotypes with alcohol dependence in Koreans. Alcohol Clin. Exp. Res. 28(7), 986-990 (2004).
61. Bart G, Kreek MJ, Ott J, et al. Increased attributable risk related to a functional mu-opioid receptor gene polymorphism in association with alcohol dependence in central Sweden. Neuropsychopharmacology 30(2), 417-422 (2005).
62. Zhang H, Luo X, Kranzler HR, et al. Association between two mu-opioid receptor gene (OPRM1) haplotype blocks and drug or alcohol dependence. Hum. Mol. Gen. 15(6), 807-819 (2006).
63. Xuei X, Dick D, Flury-Wetherill L, et al. Association of the kappa-opioid system with alcohol dependence. Mol. Psychiatry 11(11), 1016-1024 (2006).
64. Zhang H, Kranzler HR, Yang B-Z, Luo X, Gelernter J. The OPRD1 and OPRK1 loci in alcohol or drug dependence: OPRD1 variation modulates substance dependence risk. Mol. Psychiatry 13(5), 531-543 (2008).
65. Sierra DA, Gilbert DJ, Householder D, et al. Evolution of the regulators of G-protein signaling multigene family in mouse and human. Genomics 79(2), 9-9 (2002).
66. Zhang H, Wang F, Kranzler HR, Anton RF, Gelernter J. Variation in regulator of G-protein signaling 17 gene (RGS17) is associated with multiple substance dependence diagnoses. Behav. Brain Funct. 8, 23 (2012).
67. Jemal AA, Siegel RR, Ward EE, et al. Cancer statistics, 2008. CA Cancer J. Clin. 58(2), 71-96 (2008).
68. Matakidou AA, Eisen TT, Houlston RSR. Systematic review of the relationship between family history and lung cancer risk. Br. J. Cancer 93(7), 825-833 (2005).
69. Bailey-Wilson J, Amos C, Pinney S, et al. A major lung cancer susceptibility locus maps to chromosome 6q23-25. Am. J. Hum. Genet. 75(3), 15-15 (2004).
70. You M, Wang D, Liu P, et al. Fine mapping of chromosome 6q23-25 region in familial lung cancer families reveals RGS17 as a likely candidate gene. Clin. Cancer Res. 15(8), 2666-2674 (2009).
71. James MA, Lu Y, Liu Y, Vikis HG, You M. RGS17, an overexpressed gene in human lung and prostate cancer, induces tumor cell proliferation through the cyclic AMP-PKA-CREB pathway. Cancer Res. 69(5), 2108-2116 (2009).
72. Amos CI, Wu X, Broderick P, et al. Genome-wide association scan of tag SNPs identifies a susceptibility locus for lung cancer at 15q25.1. Nat. Genet. 40(5), 616-622 (2008).
73. Hung RJ, McKay JD, Gaborieau V, et al. A susceptibility locus for lung cancer maps to nicotinic acetylcholine receptor subunit genes on 15q25. Nature. 452(7187), 633-637 (2008).
74. Liu P, Vikis HG, Wang D, et al. Familial aggregation of common sequence variants on 15q24-25.1 in lung cancer. J. Natl Cancer Inst. 100(18), 1326-1330 (2008).
75. McKay JD, Hung RJ, Gaborieau V, et al. Lung cancer susceptibility locus at 5p15.33. Nat. Genet. 40(12), 1404-1406 (2008).
76. Thorgeirsson TE, Geller F, Sulem P, et al. A variant associated with nicotine dependence, lung cancer and peripheral arterial disease. Nature 452(7187), 638-642 (2008).
77. Wang Y, Broderick P, Webb E, et al. Common 5p15.33 and 6p21.33 variants influence lung cancer risk. Nat. Genet. 40(12), 1407-1409 (2008).
78. Liu P, Vikis HG, Lu Y, et al. Cumulative effect of multiple loci on genetic susceptibility to familial lung cancer. Cancer Epidemiol. Biomarkers Prev. 19(2), 517-524 (2010).
79. Eeles RA, Olama AAA, Benlloch S, et al. Identification of 23 new prostate cancer susceptibility loci using the iCOGS custom genotyping array. Nat. Genet. 45(4), 385-391 (2013).
80. Shaywitz AJ, Greenberg ME. CREB: a stimulus-induced transcription factor activated by a diverse array of extracellular signals. Annu. Rev. Biochem. 68, 821-861 (1999).
81. Mayr B, Montminy M. Transcriptional regulation by the phosphorylation-dependent factor CREB. Nat. Rev. Mol. Cell Biol. 2(8), 599-609 (2001).
82. Lonze BE, Ginty DD. Function and regulation of CREB family transcription factors in the nervous system. Neuron 35(4), 605-623 (2002).
83. Rosenberg D, Groussin L, Jullian E, Perlemoine K, Bertagna X, Bertherat J. Role of the PKA-regulated transcription factor Creb in development and tumorigenesis of endocrine tissues. Ann. NY Acad. Sci. 968, 65-74 (2002).
84. Cekanova M, Majidy M, Masi T, Al-Wadei HAN, Schuller HM. Overexpressed Raf-1 and phosphorylated cyclic adenosine 3́-5́-monophosphatate response element-binding protein are early markers for lung adenocarcinoma. Cancer 109(6), 1164-1173 (2007).
85. Sun Y, Fang R, Li C, et al. Hsa-mir-182 suppresses lung tumorigenesis through down regulation of RGS17 expression in vitro. Biochem. Biophys. Res. Commun. 396(2), 501-507 (2010).
86. Hooks SB, Callihan P, Altman MK, Hurst JH, Ali MW, Murph MM. Regulators of G-protein signaling RGS10 and RGS17 regulate chemoresistance in ovarian cancer cells. Mol. Cancer 9, 289-289 (2010).
87. Mills GB, Moolenaar WH. The emerging role of lysophosphatidic acid in cancer. Nat. Rev. Cancer 3(8), 582-591 (2003).
88. Yu S, Murph MM, Lu Y, et al. Lysophosphatidic acid receptors determine tumorigenicity and aggressiveness of ovarian cancer cells. J. Natl Cancer Inst. 100(22), 1630-1642 (2008).
89. Jung S, Lee S, Lee J, et al. Protein expression pattern in response to ionizing radiation in MCF-7 human breast cancer cells. Oncol. Lett. 3(1), 147-154 (2012).
90. Nieuwenhuijsen BW, Huang Y, Wang Y, Ramirez F, Kalgaonkar G, Young KH. A dual luciferase multiplexed high-throughput screening platform for protein-protein interactions. J. Biomol. Screen. 8(6), 676-684 (2003).
91. Young KH, Wang Y, Bender C, et al. Yeast-based screening for inhibitors of RGS proteins. Meth. Enzymol. 389, 277-301 (2004).
92. Roman DL, Talbot JN, Roof RA, Sunahara RK, Traynor JR, Neubig RR. Identification of small-molecule inhibitors of RGS4 using a high-throughput flow cytometry protein interaction assay. Mol. Pharmacol. 71(1), 169-175 (2007).
93. Roman DL, Ota S, Neubig RR. Polyplexed flow cytometry protein interaction assay: a novel high-throughput screening paradigm for RGS protein inhibitors. J. Biomol. Screen. 14(6), 610-619 (2009).
94. Roman DL, Blazer LL, Monroy CA, Neubig RR. Allosteric inhibition of the regulator of G protein signaling-Galpha protein-protein interaction by CCG-4986. Mol. Pharmacol. 78(3), 360-365 (2010).
95. Zielinski T, Kimple AJ, Hutsell SQ, Koeff MD, Siderovski DP, Lowery RG. Two Gai1 rate-modifying mutations act in concert to allow receptor-independent, steady-state measurements of RGS protein activity. J. Biomol. Screen. 14(10), 1195-1206 (2009).
96. Blazer LL, Roman DL, Chung A, et al. Reversible, allosteric small-molecule inhibitors of regulator of G protein signaling proteins. Mol. Pharmacol. 78(3), 524-533 (2010).
97. Mackie DI, Roman DL. Development of a novel high-throughput screen and identification of small-molecule inhibitors of the Ga-RGS17 protein-protein interaction using AlphaScreen. J. Biomol. Screen. 16(8), 869-877 (2011).
98. Uehara Y, Mochizuki M, Matsuno K, Haino T, Asai A. Novel high-throughput screening system for identifying STAT3-SH2 antagonists. Biochem. Biophys. Res. Commun. 380(3), 627-631 (2009).
99. Yi F, Zhu P, Southall N, et al. An AlphaScreen-based high-throughput screen to identify inhibitors of Hsp90-cochaperone interaction. J. Biomol. Screen. 14(3), 273-281 (2009).
100. Chen Y, Liu Y, Cottingham C, et al. Neurabin scaffolding of adenosine receptor and RGS4 regulates anti-seizure effect of endogenous adenosine. J. Neurosci. 32(8), 2683-2695 (2012).
101. Lerner TN, Kreitzer AC. RGS4 is required for dopaminergic control of striatal LTD and susceptibility to Parkinsonian motor deficits. Neuron 73(2), 347-359 (2012).